An interventional study of single tracer sentinel lymph node biopsy and Dual Tracr Sentinel lymph node biopsy in Breast Neoplasm, sponsored by King Edward Medical University. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by King Edward Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Breast Neoplasms with a site in Pakistan — 8 open to participants now, 14 under way, none of them phase 3. Breast Neoplasms · Pakistan.
Among the 52 studies in Breast Neoplasms with a site in Pakistan, this one is the 21st largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2026, is one of 25 with no phase, and was the 52nd registered.
14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →8 of the 52 studies in Breast Neoplasms with a site in Pakistan are open now. Recruiting first, the newest first:
Pakistan Institute of Living and Learning · Sites in Pakistan
Ages 18+ · Women only
Riphah International University · Sites in Pakistan
Ages 30–60 · Women only
Riphah International University · Sites in Pakistan
Ages 30–65 · Women only
Superior University · Sites in Pakistan
Ages 35–65 · Women only · Healthy volunteers
Liaquat University of Medical & Health Sciences · Sites in Pakistan
Women only
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 72 across 10,910 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 39 interventional studies, 286 across the 13 observational. Of the 34 that completed or were terminated, 11 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 52 have an industry lead sponsor. The 10 most frequent:
King Edward Medical University is the lead sponsor of 84 studies on the registry; 27 are open to participants now.
King Edward Medical University has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Breast Neoplasms with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07862426University of LahoreIncentive Spirometry With and Without Transcutaneous Electric Diaphragmatic Stimulation in Post-mastectomy Patients | 2026-12-13 |
| NCT07811635Jinnah Postgraduate Medical CentrePRISM Trial: Partial Breast Versus Whole Breast Radiation in Early Breast Cancer | 2026-12-31 |
| NCT07394946Cancer Care Hospital & Research Centre Foundation, LahoreNeoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer. | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 52 studies in Breast Neoplasms with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aim to compare the accuracy of single tracer versus dual tracer sentinel lymph node biopsy in breast carcinoma patients who have clinically positive axillary lymph nodes before neoadjuvant chemotherapy and become clinically node negative after treatment. this study evaluate sentinel lymph node identification and detection rates to determines whether single tracer sentinel lymph node biopsy provides comparable results to the dual tracer technique
Sentinel lymph node biopsy (SLNB) has become the standard method for axillary staging in clinically node-negative breast cancer, replacing axillary lymph node dissection (ALND) due to lower morbidity with equivalent oncologic outcomes . However, the role of SLNB after neoadjuvant chemotherapy (NACT) is technically challenging because chemotherapy alters lymphatic drainage, resulting in lower identification rates and higher false-negative rates compared with upfront surgery.
Large prospective trials, including the SENTINA, ACOSOG Z1071, and SN FNAC studies, have demonstrated that the use of dual-tracer techniques (radioisotope plus blue dye) and retrieval of multiple sentinel lymph nodes significantly improves detection rates and reduces false-negative rates in the Post-NACT setting .
Based on this evidence, international guidelines from NCCN, ASCO, and ESMO recommend the use of dual-tracer SLNB after NACT, particularly in patients who were initially node-positive.
Despite these recommendations, access to radioisotopes and gamma probes remains limited in low- and middle-income countries such as Pakistan. Consequently, single-tracer SLNB using blue dye alone continues to be practiced in many centers. Emerging observational studies suggest that in carefully selected patients who convert to clinically and radiologically node-negative status after NACT, single-tracer SLNB may still achieve acceptable detection rates .
However, local data evaluating the performance of single-tracer versus dual-tracer SLNB exclusively in the post-NACT setting are scarce. This study aims to address this gap by comparing both techniques in patients with clinically and radiologically negative axilla following neoadjuvant chemotherapy.
Post-NACT axillary staging remains a critical and guideline-sensitive aspect of breast cancer management. While dual-tracer SLNB is recommended to reduce false-negative rates, its routine use is limited by availability and cost in resource-constrained settings. Evaluating the feasibility and outcomes of single-tracer SLNB in post-NACT patients is therefore essential to guide safe, cost-effective, and locally applicable axillary management strategies .
OBJECTIVES:
To compare the effectiveness of single tracer versus dual tracer technique for sentinel lymph node biopsy in breast cancer patients who were node-positive before neoadjuvant chemotherapy and become clinically node-negative after chemotherapy, using axillary lymph node dissection as the reference standard.
To compare sentinel lymph node identification rate between single tracer and dual tracer techniques in ycN0 breast cancer patients.
To compare the number of sentinel lymph nodes retrieved using single versus dual tracer techniques.
To determine the false negative rate of sentinel lymph node biopsy in both groups using axillary lymph node dissection as the gold standard.
To compare operative time and procedure-related complications between the two techniques.
OPERATIONAL DEFINITION:
Sentinel Lymph Node (SLN) A sentinel lymph node is defined as the first axillary lymph node(s) that receive lymphatic drainage from the primary breast tumor, identified intraoperatively by uptake of blue dye and/or radioisotope.
Sentinel Lymph Node Biopsy (SLNB) SLNB refers to the surgical removal of sentinel lymph node(s) for histopathological evaluation in breast cancer patients for axillary staging after neoadjuvant chemotherapy.
Single-Tracer Technique Single-tracer SLNB is defined as identification of sentinel lymph node(s) using blue dye alone, injected peri - tumour or peri-areolar prior to surgery, without the use of radioisotope or gamma probe.
Dual-Tracer Technique Dual-tracer SLNB is defined as identification of sentinel lymph node(s) using a combination of blue dye and radioisotope (technetium-99m) with intraoperative localization using a gamma probe.
Post-Neoadjuvant Chemotherapy (Post-NACT) Post-NACT refers to patients who have completed all planned neoadjuvant systemic chemotherapy prior to definitive breast surgery.
Clinically Node-Negative Axilla (cN0) After NACT Clinically node-negative axilla is defined as absence of palpable axillary lymph nodes on physical examination after completion of neoadjuvant chemotherapy.
Radiologically Node-Negative Axilla After NACT
Radiologically node-negative axilla is defined as no suspicious axillary lymph nodes on ultrasound ± mammography or MRI, characterized by:
Preserved fatty hilum Cortical thickness ≤3 mm Absence of abnormal nodal morphology
Sentinel Lymph Node Detection Rate (Identification Rate) Sentinel lymph node detection rate will be defined as the proportion of patients in whom at least one sentinel lymph node is successfully identified during surgery after tracer injection.
It will be calculated as: Detection Rate =(Number of patients in whom ≥1 sentinel lymph node is identified) ÷(Total number of patients undergoing sentinel lymph node biopsy) × 100 Detection rate will be compared between single tracer and dual tracer groups. Failure of Sentinel Lymph Node Detection Failure of sentinel lymph node detection will be defined as the inability to identify any sentinel lymph node during surgery after tracer injection, requiring direct progression to axillary lymph node dissection.
Failure Rate =(Number of patients in whom no sentinel lymph node is identified) ÷ (Total number of patients undergoing SLNB) × 100 False Negative Sentinel Lymph Node Biopsy A false negative result will be defined when Sentinel lymph node biopsy shows no metastasis ,but axillary lymph node dissection reveals metastatic lymph nodes.
False Negative Rate (FNR)
False negative rate will be calculated as:
FNR =False Negatives ÷ (False Negatives + True Positives) × 100 ycN0 Status ycN0 will be defined as clinically and radiologically negative axillary lymph nodes after completion of neoadjuvant chemotherapy, assessed by: Clinical examination Axillary ultrasound ± imaging in patients who were biopsy-proven node-positive prior to chemotherapy.
Axillary Lymph Node Dissection (ALND) Axillary lymph node dissection will be defined as surgical removal of level I and level II axillary lymph nodes, performed in all study patients after sentinel lymph node biopsy to serve as the reference standard for nodal status.
Statistical Significance Statistical significance is defined as a p-value less than 0.05.
HYPOTHESIS:
The dual tracer technique has a higher sentinel lymph node identification rate and lower false-negative rate compared with the single tracer technique in breast cancer patients who become ycN0 after neoadjuvant chemotherapy.
MATERIAL AND METHODS:
STUDY DESIGN: Comparative Cross-Sectional Study STUDY POPULATION: Female breast cancer patients who have received neoadjuvant chemotherapy and are planned for sentinel lymph node biopsy.
SETTING: The study will be conducted in Breast Surgery Unit, Mayo Hospital, Lahore.
DURATION OF STUDY: Six Months after the approval of synopsis SAMPLING TECHNIQUE: Non Probability Convenient Sampling SAMPLE SIZE: Sample size of 108 patients (54 patients in each group) is estimated by using 5% level of significance, 90% power of test with expected mean value of positive lymph node in dual tracer as 4±2 and single tracer as 5±3.
The sample size was calculated using the following formula:
Where:
2 = Variance z1-α = Confidence level 95% =1.96 z1-β = Power of Test 90%
SAMPLE SELECTION:
Female breast cancer patients who have received neoadjuvant chemotherapy and are planned for sentinel lymph node biopsy.
DATA COLLECTION PROCEDURE:
A total of 110 patients fulfilling the inclusion criteria will be admitted from breast surgery unit, Mayo hospital Lahore. Ethical approval will be obtained from the Institutional Review Board. Written informed consent will be taken from all patients. Confidentiality will be maintained throughout the study. Female breast cancer patients who have positive axillary node and clipped that node received neoadjuvant chemotherapy and are planned for sentinel lymph node biopsy are randomly selected through lottery method. Patients will be divided into two groups:
Group A: Single-tracer SLNB( Isosulfan blue dye alone) Group B: Dual-tracer SLNB (radioisotope plus isosulfan blue dye) Blue dye will be injected peritumorally or periareolar30 minutes before anesthesia, while radioisotope injection will be injected 2 hours before surgery. Sentinel lymph nodes will be identified intra-operatively using blue dye visualization and gamma probe detection. Frozen section analysis will be performed .The number of nodes retrieved and intra-operative findings will be recorded. All identified sentinel lymph nodes will be excised and labeled separately .Following sentinel lymph node biopsy, all patients will undergo completion axillary lymph node dissection (ALND) irrespective of sentinel node status .All removed lymph nodes will be sent for histopathological examination.
The results of sentinel lymph node biopsy will be compared with single verses dual- tracer and the findings of axillary lymph node dissection to determine: Identification rate, False negative rate, number of sentinel lymph node retrieved, operative time, procedure related complications, residual nodal disease rate on ALND. All the data will be collected through a pre-designed performa (attached). Follow up of patients will be 1st at 3 month 2nd at 6 month.
DATA ANALYSIS PRODECURE:
Data will be entered and analyzed by using spss v26.0. Continuous variables such as age, tumor size, number of sentinel lymph nodes retrieved, and operative time will be presented as mean ± standard deviation or median with interquartile range depending on data distribution. Comparison between the two groups will be performed using the independent t-test or Mann-Whitney U test.
Categorical variables such as sentinel lymph node identification rate, sentinel lymph node positivity, false-negative rate, and procedure-related complications will be expressed as frequencies and percentages. Comparisons between groups will be performed using the Chi-square test or Fisher's exact test where appropriate.
The findings of sentinel lymph node biopsy will be compared with axillary lymph node dissection (gold standard) to calculate :False negative rate (FNR).A p-value ≤ 0.05 will be considered statistically significant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
By Using 1.5 cc Blue dye and inject sub dermal in peri areolar , retroareolar and peritumoural area about 20 mints before start of surgery
Procedure: single tracer sentinel lymph node biopsy
Radioisotope dye inject subdermally at 4 point 3, 6, 9,12 o clock periareolar area 3hrs before surgery and then just 20 mint before surgery inject 1.5 cc of isosulfan blue subdermal periareolar area or retroarelar area
Procedure: Dual Tracr Sentinel lymph node biopsy
By Using 1.5 cc Blue dye and inject sub dermal in peri areolar , retroareolar and peritumoural area about 20 mints before start of surgery
radio isotope dye inject at 4 point 3,6,9,12 periareolar subdermal 3 hrs before surgery and isosulfan blue dye injected 20 mint before surgery at periareolar area subdermally
Sentinel Lymph Node Identification Rate:It will be defined as the proportion of patients in whom at least one sentinel lymph node is successfully identified during surgery using either single tracer or dual tracer technique.
Sentinel Lymph Node Identification Rate:It will be defined as the proportion of patients in whom at least one sentinel lymph node is successfully identified during surgery using either single tracer or dual tracer technique.Identification rate will be calculated as:This outcome will be compared between the single tracer group and dual tracer group.
Time frame: peri operatively at the time of sentinel lymph node biopsy , following administration of the allocated single or dual tracer technique
false negative rate of sentinel lymph node biopsy
False negative rate will be defined as the proportion of patients in whom sentinel lymph node biopsy is negative but axillary lymph node dissection reveals metastatic lymph nodes.
Time frame: within 10 days after surgery, following availability of final histopathological results of completion axillary lymph node dissection specimens
Number of Sentinel Lymph Nodes:
Number of sentinel lymph nodes Retrieved The total number of sentinel lymph nodes removed during surgery will be recorded and compared between the single tracer and dual tracer groups
Time frame: with in 1 hrs after histopathology Report of sentinel lymph node biopsy recieved
Operative Time:
The time required to identify and retrieve sentinel lymph nodes will be recorded and compared between both groups.
Time frame: From the start of surgical procedure to completion of procedure measured intraoperativley and recorded in minutes
Incidence of Procedure-Related Complications
The proportion of patients experiencing procedure-related complications, including allergic reactions to the tracer or dye, seroma, surgical site infection, and lymphoedema, will be assessed and compared between the single-tracer and dual-tracer groups. Results will be reported as the number and percentage of patients experiencing each complication.
Time frame: From the time of surgery until 30 days postoperatively.
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Oct 2026, 5 months.
Of 2,666 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 5 months is below that.
Counting every sponsor, half of 2,776 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
King Edward Medical University